GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (CHIX:BSLNz) » Definitions » Interest Expense

Basilea Pharmaceutica (CHIX:BSLNZ) Interest Expense : CHF-7.9 Mil (TTM As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Basilea Pharmaceutica Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Basilea Pharmaceutica's interest expense for the six months ended in Jun. 2024 was CHF -2.5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was CHF-7.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Basilea Pharmaceutica's Operating Income for the six months ended in Jun. 2024 was CHF 9.5 Mil. Basilea Pharmaceutica's Interest Expense for the six months ended in Jun. 2024 was CHF -2.5 Mil. Basilea Pharmaceutica's Interest Coverage for the quarter that ended in Jun. 2024 was 3.77. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Basilea Pharmaceutica Interest Expense Historical Data

The historical data trend for Basilea Pharmaceutica's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Interest Expense Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.42 -7.59 -8.15 -9.85 -11.20

Basilea Pharmaceutica Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.82 -6.03 -5.80 -5.41 -2.52

Basilea Pharmaceutica Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-7.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica  (CHIX:BSLNz) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Basilea Pharmaceutica's Interest Expense for the six months ended in Jun. 2024 was CHF-2.5 Mil. Its Operating Income for the six months ended in Jun. 2024 was CHF9.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was CHF110.4 Mil.

Basilea Pharmaceutica's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage=-1* Operating Income (Q: Jun. 2024 )/Interest Expense (Q: Jun. 2024 )
=-1*9.516/-2.521
=3.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Basilea Pharmaceutica Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (CHIX:BSLNz) » Definitions » Interest Expense
Comparable Companies
XSWX:IDIA XSWX:MOLN XSWX:NWRN XSWX:XLS XSWX:SANN XSWX:RLF XSWX:ADXN VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE MRNA SMMT UTHR
Traded in Other Exchanges
BPMUF:USA 0QNA:UK BSLN:Switzerland
Address
Hegenheimermattweg 167b, Allschwil, CHE, 4123
Website
https://www.basilea.com
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica Headlines

No Headlines